Healthy Returns: Drugmakers are capping inhaler prices at $35

Three drugmakers are capping out-of-pocket costs for their inhalers. Meanwhile, many digital diabetes management tools aren't all they're cracked up to be.

Related Keywords

United States ,France ,United Kingdom ,Germany ,Americans ,British ,Combivent Respimat ,Eli Lilly ,Astrazeneca ,Glaxosmithkline ,Teva Pharmaceuticals ,Novo Nordisk ,Boehringer Ingelheim ,Senate Committee On Health ,Bernie Sanders ,Senate Committee ,Biotech And Pharmaceuticals ,Health Care Industry ,Astrazeneca Plc ,Gsk Plc ,Business News ,